Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Towa Pharmaceutical Co., Ltd.

Capitalization 210B 1.32B 1.14B 1.03B 985M 1.8B 122B 1.85B 12.18B 4.85B 58.22B 4.95B 4.85B P/E ratio 2026 *
10.5x
P/E ratio 2027 * 10.4x
Enterprise value 385B 2.42B 2.1B 1.89B 1.81B 3.3B 224B 3.39B 22.36B 8.91B 107B 9.1B 8.91B EV / Sales 2026 *
1.39x
EV / Sales 2027 * 1.26x
Free-Float
47.41%
Yield 2026 *
1.84%
Yield 2027 * 1.96%
02-13 Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
01-21 Towa Pharmaceutical Concludes A Basic Agreement with Otsuka Pharmaceutical to Establish A Collaborative Framework for Pharmaceutical Manufacturing CI
01-21 Towa Pharmaceutical, Otsuka Agree on Manufacturing Tie-Up to Secure Drug Supply MT
01-21 Towa Pharmaceutical Co Ltd - Notice of conclusion of a basic agreement with Otsuka Pharmaceutical to establish a collaborative framework for pharmaceutical manufacturing RE
11-10 Towa Pharmaceutical Co., Ltd. Announces Cash Dividend for the Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025 CI
06/08/25 Towa Pharmaceutical Says Yamagata Plant Fire Caused by Static Electricity MT
16/07/25 Japanese Shares End Marginally Lower Despite Improving July Business Sentiment MT
16/07/25 Towa Pharmaceutical Reports No Injuries in Yamagata Plant Fire, Operations Resuming MT
15/07/25 Japanese Shares Rise Ahead of Tokyo Trade Talks With US MT
15/07/25 Towa Pharmaceutical Reports Fire at Yamagata Plant; No Injuries MT
25/06/25 Towa Pharmaceutical Co., Ltd. Appoints Osamu Uchikawa as Executive Managing Director from Prior Role of Director, Effective June 25, 2025 CI
15/05/25 Towa Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Full Year Ending March 31, 2026 CI
15/05/25 Towa Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day+2.16%
1 week+0.83%
Current month-3.40%
1 month+13.45%
3 months+21.19%
6 months+42.71%
Current year+17.03%
1 week 4,000
Extreme 4000
4,415
1 month 3,705
Extreme 3705
4,445
Current year 3,465
Extreme 3465
4,445
1 year 2,298
Extreme 2298
4,445
3 years 1,703
Extreme 1703
4,445
5 years 1,703
Extreme 1703
4,445
10 years 1,193.33
Extreme 1193.3333
4,445
Manager TitleAgeSince
President 74 01/06/1996
Chief Administrative Officer - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 74 01/12/1983
Director/Board Member 77 01/06/2015
Director/Board Member 71 27/06/2017
Change 5d. change 1-year change 3-years change Capi.($)
+2.16%+0.83%+53.13%+121.07% 1.3B
-0.41%-0.80%+20.81%+206.81% 895B
-0.21%-1.06%+46.32%+58.56% 587B
+0.51%-3.59%+6.61%+49.85% 401B
-1.55%-8.03%+11.30%+24.88% 345B
-0.62%-5.04%+26.69%+62.26% 300B
-1.16%-4.00%+26.17%+35.54% 306B
-0.67%-3.53%+22.48%+9.74% 289B
+0.35%-1.05%+17.69%+60.95% 202B
-1.44%-1.21%+27.96%+84.16% 184B
Average -0.39%-1.93%+25.92%+71.38% 351.18B
Weighted average by Cap. -0.58%-1.91%+23.83%+87.81%

Financials

2026 *2027 *
Net sales 278B 1.75B 1.51B 1.36B 1.31B 2.38B 161B 2.45B 16.13B 6.43B 77.14B 6.56B 6.43B 297B 1.87B 1.61B 1.46B 1.39B 2.54B 172B 2.61B 17.22B 6.86B 82.32B 7B 6.86B
Net income 20.02B 126M 109M 98.35M 94.06M 171M 11.63B 176M 1.16B 463M 5.56B 473M 463M 20.2B 127M 110M 99.23M 94.9M 173M 11.73B 178M 1.17B 468M 5.61B 477M 467M
Net Debt 175B 1.1B 954M 861M 824M 1.5B 102B 1.54B 10.18B 4.06B 48.69B 4.14B 4.06B 164B 1.03B 891M 804M 769M 1.4B 95.07B 1.44B 9.51B 3.79B 45.46B 3.87B 3.79B
Logo Towa Pharmaceutical Co., Ltd.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Employees
4,788
Date Price Change Volume
11/03/26 4,260.00 ¥ +2.16% 113,400
10/03/26 4,170.00 ¥ +1.21% 104,900
09/03/26 4,120.00 ¥ -1.90% 177,200
06/03/26 4,200.00 ¥ +1.20% 141,800
05/03/26 4,150.00 ¥ +4.01% 202,500
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4,260.00JPY
Average target price
4,680.00JPY
Spread / Average Target
+9.86%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW